Physician profile
Amy Paugh
NPI 1578002283
$4,134.94
in general payments reported to CMS, 2019-2025
38 companies · $472 in 2025
The $472 reported for 2025 was more than what 76% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,328 · 2022: $963 · 2023: $782 · 2024: $589 · 2025: $472.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,843.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,843.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $586.84 | 2021-2025 | Relistor |
| Abbvie INC. | $517.40 | 2021-2024 | |
| Amgen INC. | $505.78 | 2021-2023 | Aimovig |
| Medtronic, INC. | $324.10 | 2021-2025 | Intellis Adaptivestim |
| Abbott Laboratories | $309.19 | 2021-2024 | Eterna, Proclaim |
| Lilly USA, LLC | $176.49 | 2021-2023 | Reyvow, Emgality |
| Boston Scientific Corporation | $169.72 | 2023-2025 | Wavewriter Alpha Prime 16, Intracept |
| Idorsia Pharmaceuticals US INC | $135.35 | 2022-2024 | Quviviq |
| Ferring Pharmaceuticals INC. | $126.76 | 2021-2023 | Euflexxa |
| Biohaven Pharmaceutical Holding Company Ltd. | $125.46 | 2022 | |
| Redhill Biopharma INC. | $118.08 | 2021 | |
| Almatica Pharma LLC | $109.18 | 2021-2023 | Gralise |
| Lundbeck LLC | $99.84 | 2022-2023 | Vyepti |
| Saluda Medical Americas, INC. | $92.92 | 2025 | Evoke |
| Radius Health, INC. | $72.87 | 2021 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Globus Medical, INC. | $71.19 | 2025 | Acp, Senza |
| Scilex Pharmaceuticals INC. | $59.21 | 2021-2024 | |
| Nevro Corp. | $58.80 | 2021-2024 | Senza |
| Bioventus LLC | $57.68 | 2022-2024 | Gelsyn-3 |
| Pfizer INC. | $49.29 | 2021-2025 | |
| Painteq LLC | $31.26 | 2023-2024 | Painteq |
| Spr Therapeutics, INC | $31.26 | 2025 | Sprint Pns System |
| Grt US Holding, INC. | $28.29 | 2021 | |
| Hydrocision, INC. | $28.09 | 2024 | Tenjet |
| Biohaven Pharmaceuticals, INC. | $24.47 | 2021 | |
| Protega Pharmaceutials INC | $23.57 | 2023 | Roxybond |
| Biogen, INC. | $23.13 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $20.89 | 2022 | |
| Allergan, INC. | $20.45 | 2021 | |
| Eisai INC. | $20.13 | 2021 | |
| Horizon Therapeutics Plc | $17.48 | 2023 | Krystexxa |
| Nalu Medical, INC. | $16.52 | 2023 | Nalu Neurostimulation System |
| Curonix LLC | $16.47 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Valinor Pharma, LLC | $13.69 | 2024 | Movantik |
| Masimo Corporation | $13.41 | 2023 | Patient Safetynet System |
| Novartis Pharmaceuticals Corporation | $13.31 | 2021 | |
| Convatec INC. | $13.26 | 2024 | |
| Virtus Pharmaceuticals LLC | $13.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Paugh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.